These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 11916929)

  • 1. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
    Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
    Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
    Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
    Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
    Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
    Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
    Brand CL; Sturis J; Gotfredsen CF; Fleckner J; Fledelius C; Hansen BF; Andersen B; Ye JM; Sauerberg P; Wassermann K
    Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E841-54. PubMed ID: 12475752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
    Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
    Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
    Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
    J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
    Chakrabarti R; Vikramadithyan RK; Kumar MP; Kumar SK; Mamidi NV; Misra P; Suresh J; Hiriyan J; Rao CS; Rajagopalan R
    Diabetes Obes Metab; 2002 Sep; 4(5):319-28. PubMed ID: 12190995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis.
    Guo Q; Sahoo SP; Wang PR; Milot DP; Ippolito MC; Wu MS; Baffic J; Biswas C; Hernandez M; Lam MH; Sharma N; Han W; Kelly LJ; MacNaul KL; Zhou G; Desai R; Heck JV; Doebber TW; Berger JP; Moller DE; Sparrow CP; Chao YS; Wright SD
    Endocrinology; 2004 Apr; 145(4):1640-8. PubMed ID: 14701675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
    Smith SA; Lister CA; Toseland CD; Buckingham RE
    Diabetes Obes Metab; 2000 Dec; 2(6):363-72. PubMed ID: 11225966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
    Ljung B; Bamberg K; Dahllöf B; Kjellstedt A; Oakes ND; Ostling J; Svensson L; Camejo G
    J Lipid Res; 2002 Nov; 43(11):1855-63. PubMed ID: 12401884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance and its treatment by thiazolidinediones.
    Lebovitz HE; Banerji MA
    Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
    Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
    Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
    Gee MK; Zhang L; Rankin SE; Collins JN; Kauffman RF; Wagner JD
    Metabolism; 2004 Sep; 53(9):1121-5. PubMed ID: 15334371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
    Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
    Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
    Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.